Evaluate the expected performance of Moderna (MRNA) for the quarter ended June 2025, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for ...

We expect Moderna MRNA to surpass expectations when it reports second-quarter 2025 earnings on Aug. 1, before the opening ...

New weekly-paying option ETFs let income investors earn dividends daily, but come with big risks and unknowns. See why ...

Corporate Counsel, in partnership with ALM Intelligence, on Monday released its 2025 General Counsel Report, an exclusive ...

While most commercial office landlords are still hunting for post‑pandemic tenants, there's a sector of the real estate industry that's breeding breakout growth: life sciences. Global biotech spending ...

Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various ...

The S&P 500 and the Nasdaq Composite ended Thursday's session with fresh record closes after scoring new all-time intraday ...

For investors, staying informed about market sentiments and expectations in the industry is paramount. This analysis provides an exploration of the latest insights on Exelixis. The consensus rating ...

Another FTSE 100-listed ( ^FTSE) giant reporting in the week ahead is pharmaceuticals company AstraZeneca ( AZN.L ), which ...

Moderna (MRNA) closed at $34.01 in the latest trading session, marking a -1.9% move from the prior day. This change lagged the S&P 500's daily gain of 0.07%. Meanwhile, the Dow lost 0.7%, and the ...

You should consider the Invesco S&P 500 Equal Weight Health Care ETF (RSPH), a passively managed exchange traded fund launched on 11/01/2006. An increasingly popular option among retail and ...

The race to develop effective cancer vaccines has entered a new phase, with late-stage trials from companies like Moderna ...